119 related articles for article (PubMed ID: 11893351)
1. Squeezing more cost and care out of dialysis: our patients would pay the price.
Meyer KB; Kassirer JP
Am J Med; 2002 Feb; 112(3):232-4. PubMed ID: 11893351
[No Abstract] [Full Text] [Related]
2. Evolution of recombinant human erythropoietin usage in clinical practice in the United States. Is there an optimal way to use rHuEPO?
Besarab A; McCrea JB
ASAIO J; 1993; 39(1):11-8. PubMed ID: 8439674
[No Abstract] [Full Text] [Related]
3. Medicare and erythropoietin.
Steinbrook R
N Engl J Med; 2007 Jan; 356(1):4-6. PubMed ID: 17202449
[No Abstract] [Full Text] [Related]
4. Impact of the change in CMS billing rules for erythropoietin on hemoglobin outcomes in dialysis patients.
Ofsthun NJ; Lazarus JM
Blood Purif; 2007; 25(1):31-5. PubMed ID: 17170534
[TBL] [Abstract][Full Text] [Related]
5. A star rises, another fades.
Neumann ME
Nephrol News Issues; 2013 Jul; 27(8):8. PubMed ID: 23926618
[No Abstract] [Full Text] [Related]
6. Major declines in epoetin dosing after prospective payment system based on dialysis facility organizational status.
Thamer M; Zhang Y; Kaufman J; Kshirsagar O; Cotter D; Hernán MA
Am J Nephrol; 2014; 40(6):554-60. PubMed ID: 25592645
[TBL] [Abstract][Full Text] [Related]
7. Recombinant erythropoietin and Medicare payment.
Sisk JE; Gianfrancesco FD; Coster JM
JAMA; 1991 Jul; 266(2):247-52. PubMed ID: 2056627
[TBL] [Abstract][Full Text] [Related]
8. Historical clinical and economic consequences of anemia management in patients with end-stage renal disease on dialysis using erythropoietin stimulating agents versus routine blood transfusions: a retrospective cost-effectiveness analysis.
Naci H; de Lissovoy G; Hollenbeak C; Custer B; Hofmann A; McClellan W; Gitlin M
J Med Econ; 2012; 15(2):293-304. PubMed ID: 22115328
[TBL] [Abstract][Full Text] [Related]
9. Dialysis facility ownership and epoetin dosing in patients receiving hemodialysis.
Thamer M; Zhang Y; Kaufman J; Cotter D; Dong F; Hernán MA
JAMA; 2007 Apr; 297(15):1667-74. PubMed ID: 17440144
[TBL] [Abstract][Full Text] [Related]
10. Finding a rational approach to ESA therapy--for payers and patients.
Messana A
Nephrol News Issues; 2007 Sep; 21(10):54, 56. PubMed ID: 17918481
[No Abstract] [Full Text] [Related]
11. Dialysis facility profit status and compliance with a black box warning.
Ishida JH; McCulloch CE; Dudley RA; Grimes BA; Johansen KL
JAMA Intern Med; 2013 Jun; 173(12):1152-3. PubMed ID: 23699967
[No Abstract] [Full Text] [Related]
12. Erythropoietin--trials then tribulation.
Stewart WK
Scott Med J; 1991 Feb; 36(1):3-4. PubMed ID: 1903215
[No Abstract] [Full Text] [Related]
13. Access to recombinant erythropoietin by Medicare-entitled dialysis patients in the first year after FDA approval.
Powe NR; Griffiths RI; de Lissovoy G; Anderson GF; Watson AJ; Greer JW; Herbert RJ; Eggers PW; Milam RA; Whelton PK
JAMA; 1992 Sep; 268(11):1434-40. PubMed ID: 1512912
[TBL] [Abstract][Full Text] [Related]
14. The possible effects of CMS's 'non-decision' on a national coverage decision for ESA therapy.
Cotter D; Thamer M; Zhang Y
Nephrol News Issues; 2011 Aug; 25(9):15-6, 18. PubMed ID: 21905526
[No Abstract] [Full Text] [Related]
15. Erythropoietin, the FDA, and oncology.
Steinbrook R
N Engl J Med; 2007 Jun; 356(24):2448-51. PubMed ID: 17568025
[No Abstract] [Full Text] [Related]
16. Cost of treating predialysis patients with recombinant human erythropoietin.
Durand-Zaleski I; Goldfarb B; Blum-Boisgard C; Drüeke T; Kreis H
Nephrol Dial Transplant; 1993; 8(4):311-4. PubMed ID: 8390004
[TBL] [Abstract][Full Text] [Related]
17. Anemia management under a bundled payment policy for dialysis: a preview for the United States from Japan.
Wish JB
Kidney Int; 2011 Feb; 79(3):265-7. PubMed ID: 21228798
[TBL] [Abstract][Full Text] [Related]
18. The cost (and quality) of health care.
Neumann ME
Nephrol News Issues; 2013 Feb; 27(2):12. PubMed ID: 23472268
[No Abstract] [Full Text] [Related]
19. Rebates for anti-anemia drugs draw response from FDA, CMS.
Sipkoff M
Manag Care; 2007 Jun; 16(6):17-8. PubMed ID: 17682732
[No Abstract] [Full Text] [Related]
20. Continuous erythropoietin receptor activator (Mircera) for renal anemia.
McGahan L
Issues Emerg Health Technol; 2008 Feb; (113):1-6. PubMed ID: 18354858
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
